Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives
International Journal of Molecular Sciences · 20.01.2026 · 27 (2) · 1025
DOI: 10.3390/ijms27021025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.01.2026. Verfasst von Maria Chiara Montalbano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Functional Genomics Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy. Hauptthemen laut MEDLINE: Immunoconjugates, Hematologic Neoplasms, Antineoplastic Agents, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Italian Ministry of University and Research, Italian Ministry of Health.
Abstract (Originalsprache)
The therapeutic landscape for hematological malignancies has been fundamentally revolutionized over the last decade by the introduction of targeted antibodies. Notably, antibody–drug conjugates (ADCs) have emerged as a critical breakthrough, significantly improving the efficacy of immune-based treatment. ADCs function as highly sophisticated delivery systems: a selective monoclonal antibody recognizes a specific cell-surface target, guiding a potent toxic payload, attached via a chemical linker, directly into the cancer cell upon internalization. Intensive research has been dedicated to optimizing these components—improving antibody selectivity, enhancing linker stability, and utilizing highly effective payloads—which has resulted in a plethora of compounds that have reached patients’ bedsides and improved the clinical course of different tumors. This review provides a crucial overview of the current landscape of approved ADCs for hematological malignancies. It critically discusses their existing limitations and details the essential structural and chemical improvements that have yielded more potent and selective next-generation tools, finally presenting future strategies to generate highly effective “bullets” capable of decisively improving long-term disease prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Functional Genomics Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
ORCID-Profile: Silvia Deaglio, Tiziana Vaisitti
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- Italian Ministry of University and Research
- Italian Ministry of Health
Zitieren
APA
Montalbano, M. C., Micillo, M., Deaglio, S., & Vaisitti, T. (2026). Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives. International Journal of Molecular Sciences, 27(2), 1025. https://doi.org/10.3390/ijms27021025
Vancouver
Montalbano MC, Micillo M, Deaglio S, Vaisitti T. Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives. International Journal of Molecular Sciences. 2026;27(2):1025. doi:10.3390/ijms27021025
BibTeX
@article{Montalbano2026,
author = {Montalbano, Maria Chiara and Micillo, Matilde and Deaglio, Silvia and Vaisitti, Tiziana},
title = {Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {1025},
doi = {10.3390/ijms27021025}
}
EUVIMED